The joint research, which builds on Fujitsu’s recent collaborative efforts with the Institute of Medical Science at the University of Tokyo and AI technologies, will draw on knowledge and issues identified through the research and clinical studies of cancer genome medical care at Aichi Cancer Center, as well as large-scale genomic data and medical records held by the Center.
Ultimately, the results of the joint research by Aichi Cancer Center and Fujitsu will lead to the development of various AI technologies that offer the potential to innovate cancer genome medical care at Aichi Cancer Center and affiliated medical institutions.
Background and details
The Aichi Cancer Center in Japan aims to establish a system that links the results of multigene panel testing for cancer to future, advanced medical care for cancer patients.
In the emergent field of genomic cancer medicine, a board of molecular tumor specialists interprets the results of a patient’s cancer gene profile to formulate appropriate treatment plans based on their unique circumstances. This process remains very time consuming, however, proving a challenge for the Aichi Cancer Center and other institutions engaged in this field. As the number of genetic tests increases, the burden on doctors, who must interpret results on an individual basis, continues to mount.
To address this challenge, Fujitsu and Aichi Cancer Center intend to create a new AI technology to improve the viability of cancer genomic medicine, drawing on technology initially developed by Fujitsu in a joint research project with the Institute of Medical Science at the University of Tokyo.
The new technology will be developed using aggregated data for genomic and clinical profiles mainly for solid cancers held in trust by the Aichi Cancer Center, with the main purpose of improving the efficiency of interpreting the results of comprehensive genomic analyses. The project will focus on improving functions that can clarify the relationship between genomic profiles in cancers and their responsiveness to anti-cancer reagents for cancer therapies.
The goal of the initiative is to ultimately expand the scope of cancers that can be targeted by genomic medicine and to deliver treatments optimized for each patient.
Future plans of Fujitsu and Aichi
Fujitsu Laboratories and the Aichi Cancer Center will integrate the results of the joint research into a series of functions that supports cancer genomic medicine together with AI technology developed to date, and apply these to hospitals in the Tokai region.
In addition, cancer genome data for various cases collected from patients at hospitals will be registered in a common reference database, which will be continuously expanded to develop integrated functions that enable more comprehensive and reliable selection of anti-cancer drugs.
This joint research initiative will allow the two institutions to make a significant contribution to the advancement of cancer genomic medicine in Japan.